A new trading day began on Monday, with CRISPR Therapeutics AG (NASDAQ: CRSP) stock price up 4.96% from the previous day of trading, before settling in for the closing price of $47.36. CRSP’s price has ranged from $38.16 to $91.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 33402.13% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -189.86%. With a float of $81.47 million, this company’s outstanding shares have now reached $85.17 million.
In an organization with 407 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 24.29%, operating margin of -176.44%, and the pretax margin is -130.91%.
CRISPR Therapeutics AG (CRSP) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.35%, while institutional ownership is 62.98%. The most recent insider transaction that took place on Oct 14 ’24, was worth 50,399. In this transaction General Counsel and Secretary of this company sold 1,089 shares at a rate of $46.28, taking the stock ownership to the 62,597 shares. Before that another transaction happened on Oct 14 ’24, when Company’s Chief Executive Officer sold 4,293 for $46.28, making the entire transaction worth $198,680. This insider now owns 226,540 shares in total.
CRISPR Therapeutics AG (CRSP) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -1.41 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -189.86% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Here are CRISPR Therapeutics AG’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.23, a number that is poised to hit -1.42 in the next quarter and is forecasted to reach -4.91 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Let’s dig in a bit further. During the last 5-days, its volume was 1.32 million. That was inferior than the volume of 1.45 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 66.58%. Additionally, its Average True Range was 1.65.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 25.72%, which indicates a significant decrease from 86.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.36% in the past 14 days, which was lower than the 45.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.22, while its 200-day Moving Average is $58.47. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $50.89. Second resistance stands at $52.07. The third major resistance level sits at $53.64. If the price goes on to break the first support level at $48.14, it is likely to go to the next support level at $46.57. The third support level lies at $45.39 if the price breaches the second support level.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
With a market capitalization of 4.23 billion, the company has a total of 84,918K Shares Outstanding. Currently, annual sales are 371,210 K while annual income is -153,610 K. The company’s previous quarter sales were 520 K while its latest quarter income was -126,410 K.
